221 related articles for article (PubMed ID: 8795617)
41. Common quantitative trait loci for alcohol-related behaviors and central nervous system neurotensin measures: hypnotic and hypothermic effects.
Erwin VG; Markel PD; Johnson TE; Gehle VM; Jones BC
J Pharmacol Exp Ther; 1997 Feb; 280(2):911-8. PubMed ID: 9023306
[TBL] [Abstract][Full Text] [Related]
42. Neurotensin modulates the electrical activity of frog pituitary melanotropes via activation of a G-protein-coupled receptor pharmacologically related to both the NTS1 and nts2 receptors of mammals.
Belmeguenai A; Vaudry H; Leprince J; Vivet B; Cavelier F; Martinez J; Louiset E
Neuroendocrinology; 2000 Dec; 72(6):379-91. PubMed ID: 11146421
[TBL] [Abstract][Full Text] [Related]
43. The signaling signature of the neurotensin type 1 receptor with endogenous ligands.
Besserer-Offroy É; Brouillette RL; Lavenus S; Froehlich U; Brumwell A; Murza A; Longpré JM; Marsault É; Grandbois M; Sarret P; Leduc R
Eur J Pharmacol; 2017 Jun; 805():1-13. PubMed ID: 28341345
[TBL] [Abstract][Full Text] [Related]
44. Neurotensin receptors in human neoplasms: high incidence in Ewing's sarcomas.
Reubi JC; Waser B; Schaer JC; Laissue JA
Int J Cancer; 1999 Jul; 82(2):213-8. PubMed ID: 10389755
[TBL] [Abstract][Full Text] [Related]
45. In vivo and in vitro structure-activity studies with peptide and pseudopeptide neurotensin analogs suggest the existence of distinct central neurotensin receptor subtypes.
Labbé-Jullié C; Dubuc I; Brouard A; Doulut S; Bourdel E; Pelaprat D; Mazella J; Martinez J; Rostène W; Costentin J
J Pharmacol Exp Ther; 1994 Jan; 268(1):328-36. PubMed ID: 8301574
[TBL] [Abstract][Full Text] [Related]
46. Activation of receptor gene transcription is required to maintain cell sensitization after agonist exposure. Study on neurotensin receptor.
Najimi M; Souazé F; Méndez M; Hermans E; Berbar T; Rostène W; Forgez P
J Biol Chem; 1998 Aug; 273(34):21634-41. PubMed ID: 9705296
[TBL] [Abstract][Full Text] [Related]
47. Neuromedin N: high affinity interaction with brain neurotensin receptors and rapid inactivation by brain synaptic peptidases.
Checler F; Vincent JP; Kitabgi P
Eur J Pharmacol; 1986 Jul; 126(3):239-44. PubMed ID: 3019713
[TBL] [Abstract][Full Text] [Related]
48. Immunological recognition of different forms of the neurotensin receptor in transfected cells and rat brain.
Boudin H; Grauz-Guyon A; Faure MP; Forgez P; Lhiaubet AM; Dennis M; Beaudet A; Rostene W; Pelaprat D
Biochem J; 1995 Jan; 305 ( Pt 1)(Pt 1):277-83. PubMed ID: 7826341
[TBL] [Abstract][Full Text] [Related]
49. Preparation and receptor binding affinities of cyclic C-terminal neurotensin (8-13) and (9-13) analogues.
Lundquist JT; Dix TA
Bioorg Med Chem Lett; 1999 Sep; 9(17):2579-82. PubMed ID: 10498212
[TBL] [Abstract][Full Text] [Related]
50. Evidence of
Marenco M; Lodola L; Persico MG; Frangipane V; Facoetti A; Aprile C; Hodolič M
Curr Pharm Biotechnol; 2018; 19(9):754-759. PubMed ID: 30160211
[TBL] [Abstract][Full Text] [Related]
51. Involvement of the neurotensin receptor subtype NTR3 in the growth effect of neurotensin on cancer cell lines.
Dal Farra C; Sarret P; Navarro V; Botto JM; Mazella J; Vincent JP
Int J Cancer; 2001 May; 92(4):503-9. PubMed ID: 11304684
[TBL] [Abstract][Full Text] [Related]
52. Intermolecular interactions between the neurotensin and the third extracellular loop of human neurotensin 1 receptor.
Da Costa G; Bondon A; Coutant J; Curmi P; Monti JP
J Biomol Struct Dyn; 2013 Dec; 31(12):1381-92. PubMed ID: 23140271
[TBL] [Abstract][Full Text] [Related]
53. In vitro analysis of stable, receptor-selective neurotensin[8-13] analogues.
Kokko KP; Hadden MK; Orwig KS; Mazella J; Dix TA
J Med Chem; 2003 Sep; 46(19):4141-8. PubMed ID: 12954066
[TBL] [Abstract][Full Text] [Related]
54. Genetic-based differences in neurotensin levels and receptors in brains of LS x SS mice.
Erwin VG; Radcliffe R; Hinkle B; Jones BC
Peptides; 1993; 14(4):821-8. PubMed ID: 8234031
[TBL] [Abstract][Full Text] [Related]
55. Differential processing of the neurotensin/neuromedin N precursor in the mouse.
Shaw C; McKay D; Johnston CF; Halton DW; Fairweather I; Kitabgi P; Buchanan KD
Peptides; 1990; 11(2):227-35. PubMed ID: 2356154
[TBL] [Abstract][Full Text] [Related]
56. The characterization and regional distribution of neuromedin N-like immunoreactivity in rat brain using a highly sensitive and specific radioimmunoassay. Comparison with the distribution of neurotensin.
de Nadai F; Cuber JC; Kitabgi P
Brain Res; 1989 Oct; 500(1-2):193-8. PubMed ID: 2605491
[TBL] [Abstract][Full Text] [Related]
57. Peptide backbone modifications on the C-terminal hexapeptide of neurotensin.
Einsiedel J; Hübner H; Hervet M; Härterich S; Koschatzky S; Gmeiner P
Bioorg Med Chem Lett; 2008 Mar; 18(6):2013-8. PubMed ID: 18276136
[TBL] [Abstract][Full Text] [Related]
58. Regulation of DARPP-32 Thr75 phosphorylation by neurotensin in neostriatal neurons: involvement of glutamate signalling.
Matsuyama S; Fukui R; Higashi H; Nishi A
Eur J Neurosci; 2003 Sep; 18(5):1247-53. PubMed ID: 12956723
[TBL] [Abstract][Full Text] [Related]
59. Neurotensin and neuromedin N elevate the cytosolic calcium concentration via transiently appearing neurotensin binding sites in cultured rat cortex cells.
Sato M; Shiosaka S; Tohyama M
Brain Res Dev Brain Res; 1991 Jan; 58(1):97-103. PubMed ID: 1849803
[TBL] [Abstract][Full Text] [Related]
60. Topography of the neurotensin (NT)(8-9) binding site of human NT receptor-1 probed with NT(8-13) analogs.
Lundquist JT; Büllesbach EE; Golden PL; Dix TA
J Pept Res; 2002 Feb; 59(2):55-61. PubMed ID: 11906607
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
